Generic drug maker Teva Pharmaceutical Industries Ltd. said early Tuesday global sales of its multiple sclerosis drug Copaxone rose 15 percent during the third quarter to reach a record $354 million.

The drug is distributed in the United States and Europe by French Drug maker Sanofi-Aventis SA, which reported third-quarter earnings Tuesday. Teva, the world's largest generic drug developer, is based in Israel.

U.S. sales of Copaxone grew 10 percent to reach $226 million and sales in Europe and elsewhere grew 26 percent to reach $128 million.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP